CSBR Champions Oncology Inc Net Margin

Champions Oncology, Inc. - graphic logo of issuer CSBR

Champions Oncology generates revenue by conducting personalized drug tests using unique tumor models. The net profit margin illustrates cost efficiency dynamics, where the value of -1.80 reflects this status. Strong pricing power over the pharmaceutical market and a transition to a SaaS model for predictive data analysis provide the company with significant potential for business scaling.

Champions Oncology, Inc. (CSBR) - Company Sales Margin from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for Champions Oncology, Inc. (CSBR)

- market value and analyst target forecast:
- market capitalization data:
Analysis of all company metrics:championsoncology.com, CSBR
Manufactured product of championsoncology.com

For Champions Oncology (CSBR), the efficiency of developing personalized tumor models directly impacts profitability. This metric measures the share of net profit within total revenue, demonstrating the final yield of each unit of services sold. By analyzing the net operating margin, an investor assesses the business's ability to convert innovation into actual cash flow. The net operating margin trend reveals the model's resilience to operating expenses, allowing for the determination of the true financial value of this high-tech medical service.

Who Champions Oncology competes with

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|XBIT (XBiotech Inc.) - Net Sales Margin|CVM (CEL-SCI Corporation) - Company Net Profitability|Net Sales Margin OSTX|Net Sales Margin Radiopharm Theranostics Ltd (RADX)|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)